Entereg wins key FDA advisory committee vote

The FDA's gastrointestinal drug advisory committee narrowly endorsed Entereg, a new drug for postoperative ileus in bowel resection. The vote came down 9 to 6 in Entereg's favor. The FDA is considering an NDA for the drug, which is being developed by Adolor and GlaxoSmithKline. There are currently no drugs approved for this indication.

"A majority of the committee agreed that Entereg produced clinically meaningful acceleration in [gastrointestinal] recovery in bowel resection patients," said Yvonne Greenstreet, senior vice president of the medicine development center at Glaxo, in a statement. "Postoperative ileus can be uncomfortable for the patient, hinder post surgical recovery and delay hospital discharge in bowel resection patients."

- see this release
- check out the report from AFX

Related Articles:
Adolor shares rise on NDA news. Report
Investors cheer FDA's acceptance of Entereg response. Report
FDA wants more safety data on Entereg. Report
Adolor shelves Entereg studies; shares plunge. Report
FDA needs more data on Adolor drug. Report
Adolor hit by FDA's approvable letter for Entereg. Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.